1106 results
Keyword Ritonavir Sandoz Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Ritonavir Mylan
ritonavir, HIV Infections
Date of authorisation: 09/11/2017,
, Revision: 13, Authorised, Last updated: 12/10/2022
Ritonavir Mylan Blood-Borne Infections Communicable … Ritonavir Mylan … summary for the public Ritonavir Mylan ritonavir This is a summary of the … -
List item
Human medicine European public assessment report (EPAR): Lopinavir/Ritonavir Mylan
lopinavir, ritonavir, HIV Infections
Date of authorisation: 14/01/2016,, Revision: 14, Authorised, Last updated: 09/06/2022
Lopinavir/Ritonavir Mylan lopinavir / ritonavir This is a summary of the … substances lopinavir and ritonavir. Lopinavir/Ritonavir Mylan … Ritonavir Mylan lopinavir ritonavir lopinavir ritonavir … -
List item
Withdrawn application: Duloxetine Sandoz
duloxetine, date of withdrawal: 08/04/2015, Initial authorisation, Last updated: 24/04/2015Duloxetine Sandoz: Withdrawn application … Duloxetine Sandoz: Withdrawal of the marketing … application for Duloxetine Sandoz (duloxetine) On 08 April … -
List item
Human medicine European public assessment report (EPAR): Norvir
ritonavir, HIV Infections
Date of authorisation: 25/08/1996, Revision: 68, Authorised, Last updated: 18/10/2022ritonavir … Norvir, INN-ritonavir EMA/159632/2012 EMEA/H/C/000127 … for the public Norvir ritonavir This is a summary of the … -
List item
Human medicine European public assessment report (EPAR): Paxlovid (updated)
nirmatrelvir, ritonavir, COVID-19 virus infection
Date of authorisation: 28/01/2022, Revision: 10, Authorised, Last updated: 07/03/2023nirmatrelvir / ritonavir … Paxlovid (PF-07321332 / ritonavir) An overview of Paxlovid … substances, PF-07321332 and ritonavir, in two different tablets … -
List item
Human medicine European public assessment report (EPAR): Kaletra
lopinavir, ritonavir, HIV Infections
Date of authorisation: 19/03/2001, Revision: 60, Authorised, Last updated: 29/11/2022substances , lopinavir and ritonavir. How is Kaletra used? Kaletra … activity against the virus while ritonavir mainly works as a ‘booster’ … public Kaletra lopinavir / ritonavir This is a summary of the … -
List item
Direct healthcare professional communication (DHPC): Kaletra (lopinavir/ritonavir) oral solution, 2 bottle pack containing 2-ml oral dosing syringes: Presence of amide particles in 2-ml oral dosing syringes
Active substance: lopinavir, ritonavir, DHPC type: Quality defect, Last updated: 04/01/2021Kaletra Kaletra lopinavir ritonavir lopinavir ritonavir lopinavir ritonavir … -
List item
Human medicine European public assessment report (EPAR): Viekirax
Ombitasvir, paritaprevir, ritonavir, Hepatitis C, Chronic
Date of authorisation: 14/01/2015, Revision: 27, Authorised, Last updated: 12/08/2022ombitasvir / paritaprevir / ritonavir … ombitasvir / paritaprevir / ritonavir) An overview of Viekirax … ombitasvir, paritaprevir and ritonavir. How is Viekirax used? Viekirax … -
List item
Human medicine European public assessment report (EPAR): Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)
levodopa, carbidopa, entacapone, Parkinson Disease
Date of authorisation: 11/11/2013, Revision: 10, Authorised, Last updated: 16/01/2023Levodopa/Carbidopa/Entacapone Sandoz) Nervous System Diseases Neurodegenerative … Levodopa/Carbidopa/Entacapone Sandoz) : EPAR - All Authorised presentations … Levodopa/Carbidopa/Entacapone Sandoz) : EPAR - Procedural steps … -
List item
Opinion on medicine for use outside EU: Aluvia
lopinavir, ritonavir, HIV Infections, ATC code: J05AR10 Opinion number: H-W-764, Positive opinion Opinion date: 21/09/2006, Last updated: 15/12/2022public Aluvia lopinavir and ritonavir This document is a summary … substances, lopinavir and ritonavir. It is available as tablets … 100 mg lopinavir and 25 mg ritonavir; red: 200 mg lopinavir and … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kaletra, lopinavir, ritonavir
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001005-PIP01-10-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution, Capsule, soft, Film-coated tablet
Decision date: 23/07/2012, Last updated: 27/07/2015, Compliance check: V, 17/07/2015Active substance lopinavir ritonavir Therapeutic area Infectious … investigation plan for lopinavir / ritonavir (Kaletra) (EMEA-001005-PIP01-10-M01 … investigation plan for lopinavir / ritonavir (Kaletra) (EMEA-001005-PIP01-10-M01 … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Viekirax, Ombitasvir, paritaprevir, ritonavir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001440-PIP01-13-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Age-appropriate oral solid dosage form
Decision date: 12/08/2020, Last updated: 30/06/2021, Compliance check: Xsubstance Ombitasvir paritaprevir ritonavir Therapeutic area Infectious … ombitasvir / paritaprevir / ritonavir (Viekirax), (EMEA-001440-PIP01-13-M03 … ombitasvir / paritaprevir / ritonavir (Viekirax), (EMEA-001440-PIP01-13-M03 … -
List item
Human medicine European public assessment report (EPAR): Aripiprazole Sandoz
aripiprazole, Schizophrenia; Bipolar Disorder
Date of authorisation: 20/08/2015,, Revision: 9, Authorised, Last updated: 01/09/2022
Aripiprazole Sandoz Schizophrenia Spectrum and … report (EPAR) for Aripiprazole Sandoz. It explains how the Agency … on how to use Aripiprazole Sandoz. For practical information … -
List item
Human medicine European public assessment report (EPAR): Temozolomide Sandoz (updated)
temozolomide, Glioma; Glioblastoma
Date of authorisation: 15/03/2010,, Revision: 17, Withdrawn, Last updated: 06/03/2023
Temozolomide Sandoz Cancer Neuroectodermal … authorisation for Temozolomide Sandoz has been withdrawn at the … Summary documents Temozolomide Sandoz : EPAR - Summary for the … -
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz
pregabalin, Anxiety Disorders; Neuralgia; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 15, Authorised, Last updated: 05/01/2023
Pregabalin Sandoz Mental Disorders Nervous … report (EPAR) for Pregabalin Sandoz. It explains how the Agency … on how to use Pregabalin Sandoz. For practical information … -
List item
Human medicine European public assessment report (EPAR): Rivastigmine Sandoz
rivastigmine, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 10/12/2009, Revision: 13, Authorised, Last updated: 13/10/2022Rivastigmine Sandoz Nervous System Diseases Central … EPAR). What is Rivastigmine Sandoz? Rivastigmine Sandoz is a medicine containing … be used for Rivastigmine Sandoz (‘informed consent’ … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Sandoz
clopidogrel, Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 21/09/2009,, Revision: 2, Withdrawn, Last updated: 26/10/2011
Clopidogrel Sandoz Peripheral Vascular Diseases Stroke Myocardial … authorisation for Clopidogrel Sandoz has been withdrawn at the … Summary documents Clopidogrel Sandoz : EPAR - Summary for the … -
List item
Human medicine European public assessment report (EPAR): Pregabalin Sandoz GmbH
pregabalin, Anxiety Disorders; Epilepsy
Date of authorisation: 19/06/2015,, Revision: 14, Authorised, Last updated: 05/01/2023
Pregabalin Sandoz GmbH Mental Disorders Nervous … report (EPAR) for Pregabalin Sandoz GmbH. It explains how the … on how to use Pregabalin Sandoz GmbH. For practical information … -
List item
Human medicine European public assessment report (EPAR): Pemetrexed Sandoz
pemetrexed disodium hemipentahydrate, Carcinoma, Non-Small-Cell Lung; Mesothelioma
Date of authorisation: 18/09/2015,, Revision: 7, Authorised, Last updated: 27/07/2022
Pemetrexed Sandoz Carcinoma, Bronchogenic Bronchial … Pemetrexed Sandoz … for the public Pemetrexed Sandoz pemetrexed This is a summary … -
List item
Human medicine European public assessment report (EPAR): Ibandronic Acid Sandoz
ibandronic acid, Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone
Date of authorisation: 26/07/2011,, Revision: 9, Authorised, Last updated: 06/07/2022
Ibandronic Acid Sandoz Skin and Connective Tissue … EPAR) for Ibandronic Acid Sandoz. It explains how the Committee … of use for Ibandronic Acid Sandoz. What is Ibandronic Acid Sandoz? Ibandronic Acid Sandoz is a medicine that contains … -
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir, dasabuvir, sofosbuvir, ledipasvir, simeprevir, ombitasvir, paritaprevir, ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017ombitasvir / paritaprevir / ritonavir). Since the start of this review … r ombitasvir paritaprevir ritonavir sofosbuvir simeprevir ombi … r ombitasvir paritaprevir ritonavir ledispavir sofosbuvir dasa … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): darunavir, ritonavir
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-002537-PIP02-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 12/08/2020, Last updated: 18/06/2021, Compliance check: XKey facts darunavir ritonavir Infectious diseasesP/0308/2020EMEA-002537-PIP02-19 … a waiver for darunavir / ritonavir (EMEA-002537-PIP02-19) PDF … a waiver for darunavir / ritonavir (EMEA-002537-PIP02-19) in … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ritonavir, atazanavir sulfate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-002588-PIP01-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 04/12/2019, Last updated: 06/12/2022, Compliance check: XKey facts ritonavir atazanavir sulfate Infectious … for atazanavir (sulfate) / ritonavir (EMEA-002588-PIP01-19) PDF … Related documents Atazanavir / Ritonavir - Notification of discontinuation … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dasabuvir, Ombitasvir, paritaprevir, ritonavir
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001805-PIP01-15, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet
Decision date: 02/10/2015, Last updated: 17/12/2015, Compliance check: XDasabuvir Ombitasvir paritaprevir ritonavir Therapeutic area Infectious … fourth active substance, ritonavir, does not act directly against … ombitasvir, paritaprevir and ritonavir are Public summary … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): lopinavir, lamivudine, ritonavir, zidovudine
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: EMEA-001368-PIP01-12, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 30/07/2013, Last updated: 03/09/2013, Compliance check: Xfacts lopinavir lamivudine ritonavir zidovudine Infectious diseasesP/0175/2013EMEA-001368-PIP01-12 … lopinavir / lamivudine / ritonavir / zidovudine (EMEA-001368-PIP01-12 … lopinavir / lamivudine / ritonavir / zidovudine (EMEA- 001368-PIP01-12 …